79378525 - POLYPEPTIDE

Information

• Trademark
• 79378525

• Source

• Serial Number

  79378525

• Registration Number

  7616806

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 3 - Bleaching preparations and other substances for laundry use
  • 5 - Pharmaceutical and veterinary preparations
  • 35 - Advertising
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  May 05, 2023
  2 years ago

• Registration Date

  December 24, 2024
  a year ago

• Transaction Date

  December 24, 2024
  a year ago

• Status Date

  December 24, 2024
  a year ago

• Published for Opposition Date

  October 22, 2024
  a year ago

• Location Date

  December 23, 2024
  a year ago

• Status Code

  700

• Current Location

  FILE REPOSITORY (FRANCONIA)

  Employee Name

  EISNACH, MICHAEL

• Attorney Docket Number

  CONI110TM66

  Attorney Name

  Bethany J. Whelan

• Owners

  • POLYPEPTIDE LABORATORIES HOLDING (PPL) AB

Case File Statements

• GS0401: Custom manufacturing services for others in the field of peptide and olignuclotide manufacturing
• DM0000: The mark consists of a stylized atomic model in green. To the right of this design is the wording "POLYPEPTIDE" in black font. The white in the mark is background only and is not claimed as a feature of the mark.
• GS0051: Synthetic peptides for pharmaceutical purposes, namely, for use in oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; synthetic oligonucleotides for pharmaceutical purposes for use in oncology, neurology, rare diseases for the treatment of genetic disorders, neurodegenerative diseases and cancer; pharmaceutical and veterinary preparations, namely, synthetic peptides for pharmaceutical and veterinary purposes for fertility control in animals, induction of ovulation in mares, castration of dogs, facilitation of parturition in livestock; biological preparations for medical and veterinary purposes, namely, polypetide biochemicals for medical and veterinary purposes for oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; medicated dandruff and hair loss shampoos, medicated hair lotions for treating dandruff hair loss and hair damage, medicated soap cleansers for the skin, and medicated cosmetics, namely creams for treating acne, irritated, itching, and inflamed skin, repairing skin damage and promoting wound healing; medical being medicated hair lotion; medicated soap; sanitary preparations for medical purposes; medicated and sanitizing soaps and detergents; dietetic substances in the nature of protein dietary supplements; protein nutritional supplements; collagen dietary supplements; collagen nutritional supplements; collagen peptide dietary supplements; collagen peptide nutritional supplements adapted for medical use; food for babies; dietetic food adapted for medical use; dietetic food adapted for veterinary use; plasters for medical purposes; materials for dressings, namely, medical dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; vaccines
• GS0031: Non-medicated soaps; perfumery; essential oils; cosmetics; hair lotions; dentifrices
• CC0000: The color(s) green and black is/are claimed as a feature of the mark.
• GS0351: Advertising services; business administration; business management; providing office function
• GS0011: Biological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes
• DS0000: "POLYPEPTIDE"
• GS0421: Research and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucelotide manufacturing

Case File Event Statements

• 9/18/2023 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 9/14/2023 - 2 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR

• 9/22/2023 - 2 years ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 1/31/2024 - a year ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 2/7/2024 - a year ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 2/28/2024 - a year ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 3/19/2024 - a year ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 8/28/2024 - a year ago

  11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 8/28/2024 - a year ago

  12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 8/28/2024 - a year ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 2/6/2024 - a year ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/28/2024 - a year ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 9/16/2024 - a year ago

  16 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 9/16/2024 - a year ago

  13 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 9/16/2024 - a year ago

  15 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 9/16/2024 - a year ago

  14 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 9/16/2024 - a year ago

  17 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 10/2/2024 - a year ago

  18 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 10/22/2024 - a year ago

  19 - PUBLISHED FOR OPPOSITION Type: PUBO

• 10/22/2024 - a year ago

  20 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 12/24/2024 - a year ago

  21 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 12/24/2024 - a year ago

  22 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC